<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656223</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149BDE01</org_study_id>
    <nct_id>NCT04656223</nct_id>
  </id_info>
  <brief_title>Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions</brief_title>
  <acronym>ADITION</acronym>
  <official_title>Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed as a multicenter, observational, non-interventional, open label,&#xD;
      26-week study in order to observe how asthma control changes under treatment with Mometasone&#xD;
      Fuorat/Indacaterol/ Glycopyrronium (MF/IND/GLY) Breezhaler® sensor system or under treatment&#xD;
      with fixed-dose combination (FDC) triple therapy after 26 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in one group will receive MF/IND/GLY together with the Propeller add-on sensor for&#xD;
      the Breezhaler® and access to the smartphone app according to label. Subjects in the other&#xD;
      group will receive any triple FDC according to label. The physician's decision to initiate or&#xD;
      switch a patient to MF/IND/GLY Breezhaler® system or any other triple FDC must have been&#xD;
      taken prior to and independently from the decision to include the patient in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in asthma control test (ACT) score</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>ACT assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning, and overall self-assessment of asthma control.&#xD;
It is a self-administered questionnaire comprising five items that are assessed on a five point categorical scale (1 to 5) and the scores are summed to give a total score ranging from 5 to 25, with a score of &gt;=20 denoting 'controlled asthma', a score of 16-19 denoting 'partially controlled asthma', and a score of &lt;=15 denoting 'uncontrolled asthma'. The total score is calculated as the sum of the scores from all 5 questions. Higher scores indicates improved asthma control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician</measure>
    <time_frame>Baseline</time_frame>
    <description>Description of reasons for prescribing MF/IND/GLY plus sensor or triple FDC as indicated by the physician will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of of patient characteristics at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Description of patient characteristics at baseline in the treatment groups receiving MF/IND/GLY plus sensor or triple FDC will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients showing an improvement in self-reported test adherence to inhalers (TAI) questionnaire</measure>
    <time_frame>26 weeks</time_frame>
    <description>TAI test is a 12-item questionnaire designed to assess the adherence to inhalers in patients with asthma.&#xD;
Ten questions are answered by the patients, and have to rate each question from 1 to 5. Total score can go between 10 and 50; 50 points correlates to &quot;adherent&quot;, 46-49 points correlates to &quot;moderate adherent&quot; and lower than 45 points correlate to &quot;not adherent&quot;.&#xD;
Two additional questions are answered by the physician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of adherence in the subgroup receiving MF/IND/GLY plus sensor</measure>
    <time_frame>26 weeks</time_frame>
    <description>Adherence course according to inhalation tracking data in the subgroup treated with MF/IND/GLY plus sensor will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of days with adherence to treatment in the subgroup receiving MF/IND/GLY plus sensor will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the minimal clinically important difference (MCID) change</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>Percentage of patients achieving the minimal clinically important difference (MCID) change from baseline ACT ≥ 3 points will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with an ACT score &lt;19</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percentage of patients with an ACT score of &lt;19 at baseline and following 26 weeks will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post-dose trough Forced Expiratory Volume in one second (FEV1)</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>FEV 1 it is the amount that is exhaled in the first second of purposefully trying to breathe out as much air as possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced vital capacity (FVC)</measure>
    <time_frame>Baseline, week 26</time_frame>
    <description>FVC is the volume of air that can forcibly be blown out after full inspiration, measured in liters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>26 weeks</time_frame>
    <description>Adverse events will be provided</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF/IND/GLY Breezhaler® plus Propeller Health</arm_group_label>
    <description>patients receiving MF/IND/GLY Breezhaler® plus electronic inhalation tracking sensor (Propeller Health) according to label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other FDC therapy</arm_group_label>
    <description>patients receiving ICS+LABA+LAMA FDC therapy according to label</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MF/IND/GLY plus sensor system</intervention_name>
    <description>There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.&#xD;
Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label.</description>
    <arm_group_label>MF/IND/GLY Breezhaler® plus Propeller Health</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC therapy</intervention_name>
    <description>There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.</description>
    <arm_group_label>Other FDC therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be enrolled from approximately 25 pulmonology centers across Germany.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To participate in the study, all of the following inclusion criteria must be met:&#xD;
&#xD;
          1. Patients (m/f/d) at the age of ≥18&#xD;
&#xD;
          2. Written declaration of consent&#xD;
&#xD;
          3. Asthma diagnosis according to German Asthma Guideline NVL, 4th edition&#xD;
&#xD;
          4. Suitability for a therapy with MF/IND/GLY in combination with the sensor system or&#xD;
             another ICS+LABA+LAMA FDC according to SPC&#xD;
&#xD;
          5. At least 6 months of inhaled therapy with ICS+LABA (high dose) or ICS+LABA+LAMA&#xD;
             (medium or high dose) before switching or escalating asthma medication at baseline&#xD;
&#xD;
          6. Change or escalation of the asthma medication to MF/IND/GLY in combination with the&#xD;
             sensor system or another ICS+LABA+LAMA FDC according to the therapy decision of the&#xD;
             treating physician&#xD;
&#xD;
          7. Availability of at least one ACT value of the last 6 months before consent&#xD;
&#xD;
          8. Cohort treated with MF/IND/GLY in combination with the sensor system&#xD;
&#xD;
               -  Owning an Android or iOS smartphone or tablet on which the app can be installed&#xD;
                  (via WiFi or mobile data network) and run (requires about 75 megabytes of storage&#xD;
                  space) and which is capable of establishing a Bluetooth connection to the sensor&#xD;
                  The patient must agree to activate the app, the Bluetooth connection and the&#xD;
                  mobile data connection regularly (at least once a month).&#xD;
&#xD;
               -  Availability of an e-mail address&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To participate in the study, none of the following exclusion criteria must apply:&#xD;
&#xD;
          1. Use of a digital inhaler-coupled inhalation tracking system to support adherence in&#xD;
             the last 3 months prior to study entry&#xD;
&#xD;
          2. Simultaneous participation in an interventional study or in another Novartis-sponsored&#xD;
             noninterventional study&#xD;
&#xD;
          3. Asthma therapy with a biological agent, if not stable at the same dosage for at least&#xD;
             3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <state>BW</state>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunschweig</city>
        <state>Lower Saxonia</state>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxonia</state>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ibbenbueren</city>
        <state>Rheinland Pfalz</state>
        <zip>49477</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Sachsa</city>
        <zip>37441</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12672</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burgwedel</city>
        <zip>30938</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Einbeck</city>
        <zip>37574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Furstenwalde</city>
        <zip>15517</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gummersbach</city>
        <zip>51343</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hettstedt</city>
        <zip>06333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Papenburg</city>
        <zip>26871</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roth</city>
        <zip>91154</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mobile Health</keyword>
  <keyword>mHealth</keyword>
  <keyword>Propeller Health</keyword>
  <keyword>MF/IND/GLY Breezhaler®</keyword>
  <keyword>FDC</keyword>
  <keyword>Fixed dose combination</keyword>
  <keyword>Mometasone Fuorat</keyword>
  <keyword>Indacaterol</keyword>
  <keyword>Glycopyrronium</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

